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INTRODUCTION
Acute leukemia is a group of malignant diseases where genetic abnormalities in hematopoietic cells lead to unregulated clonal cell proliferation (Tubergen et al 2016) . Acute leukemia accounts for approximately 97% of cases of childhood leukemia. In development country the incidence of acute myelogenous leukemia (AML) is approximately 17% and acute lymphoblastic leukemia (ALL) is 83%. In Dr. Soetomo Hospital, throughout the 2002 there were 885 ALL, 85 ML and 4% chronic leukemia of 70 new cases of leukemia (Permono et al 2010) . Chemotherapy is the main therapy in leukemia. Neutropenia and its complications, including febrile neutropenia, are major toxicities related to myelosuppressive systemic cancer chemotherapy. This can decrease a risk of infection that causes delays in treatment and reduction of dose intensity, which reduces therapeutic outcome (Hansen et al 2010 , Bracci et al 2014 .
Human granulocyte colony-stimulating factor (GCSF) is a hematopoietic hormone that have been shown to reduce the duration and severity of neutropenia and the risk of febrile neutropenia. GCSF promotes the growth, proliferation, differentiation, and maturation of neutrophil precursors (Crawford et al 2010) . The first generation of GCSF pharmaceuticals, which recombinant derivatives, is Filgrastim (nonglycosylated) (Scholz et al 2012) .
As a result of extensive investigations, risk of neutropenia and febrile neutropenia in patients receiving myelosuppressive chemotherapy were generally lower for prophylaxis with filgrastim (Ghalaut et al 2008 , Rosary 2010 , Lyman et al 2013 , Mitchell et al 2016 . However, some research showed different results, according to several that showed the use of filgrastim in severe neutropenia induced chemoteraphy is not recommended, because there is no significant difference between the ANC increase in patients using placebo and filgrastim (Rodriguez et al 2005 , Velasco 2010 ).
The use of therapeutic filgrastim in patients with established fever and neutropenia is controversial. In developing countries, as well as in Dr. Saiful Anwar Hospital, Malang, filgrastim given as a therapy for neutropenia induced chemotherapy. The use of filgrastim for prophylaxis is difficult because the price is pretty expensive. The purpose of this study was to analyze the use of filgrastim on ANC levels changes in acute leukemia children with neutropenia, and the patient that achieve ANC level's targeted therapy = 1000 cell/mm 3 .
MATERIALS AND METHODS
This study used a prospective observational with a longitudinal design from June to October 2016 at Paediatric Departement, Hematology Division of Dr. Saiful Anwar Hospital, Malang. The inclusion criteria was children aged <18 years who diagnosed acute leukemia with neutropenia, who had received filgrastim of 10 µg/kgBW for 3, 4, 5 days, then ANC level measurement was carried out before and after filgrastim induction. This study excluded the patients who were sensitive of filgrastim, and used filgrastim for prophylaxis.
The effects and therapeutic use of filgrastim were explained at the beginning of the study. A standard medical history, clinical, and laboratory data were collected from patient information and based on medical record. The ANC was calculated from the differential leukocyte count (performed manually) and the absolute number of leucocytes (performed automatically using a Coulter counter (Sysmex NE-8000, Tao Medical Electronics, Kobe, Japan)). The ANC was measured with flow cytometry method. This study was approved by the Ethics Committee of the Dr. Saiful Anwar Hospital, Malang.
Nominal scale data were described as frequency distribution and interval scale data were described as mean, deviations standard, and medians. Data analysis was started with normality test with Shapiro Wilk. A comparative hypothesis test was performed to determine differences ANC levels between 3 and 5 days in filgrastim therapy with Paired Samples T-Test, and differences ANC levels each day with One Way Anova. The test results were statistically significant if probability (p) <0.05 with a confidence interval of 95%. Table 1 shows the baseline characteristics of patients. Twelve children were recruited for the study. The majority of children with neutropenia were female with age 0-6 years. Female displayed a higher risk for neutropenia than male. Table 2 shows ANC level changes in acute leukemia with neutropenia patients in which 7 episodes took filgrastim for 3 days, 1 episode took filgrastim for 4 day, and 7 episodes took filgrastim for 5 days. Thus, it consisted of 15 episodes. During the 5-days dosing period and the 1 postdosing day in which ANC was measured, daily ANC value showed persistent increase over the first 3-days dosing period and decreased sharply on days 4 and 5. On day 1, the ANC levels increased 82.2% and reached a maximum level in 3 days. The ANC levels decreased 87.2% on day 4. ANC levels decreased by 4.2-43.1% within 24 hours of filgrastrim discontinuity.
RESULTS
In 3 days therapy of filgrastim, ANC levels increased by 9.5 fold from 381.3 ± 91.8 cell/mm 3 to 3984.9 ± 426.8 cell/mm 3 . The ANC levels increased by 13.5 fold in 4 days therapy, but decreased by 0.9 fold in 5 days therapy. Filgrastim had increased the ANC levels unsignificanly in neutropenia patients. There were 53% neutropenia patients who achieved the goal of therapy.
DISCUSSION
In this study, most patients had ANC levels under 500 cells/mm 3 (severe neutropenia) before given with filgrastim therapy. It appears that the episodes of neutropenia may occur due to infiltration of malignant cells in the bone marrow or due to the impact of myelosuppresive chemotherapy (Pertiwi et al 2013 , Sudewi et al 2007 . Furthermore, the guidelines recognize that older age (particularly >65 years), previous chemotherapy or radiotherapy, pre-existing neutropenia or tumor involvement in the bone marrow, poor performance status, comorbidities (e.g., renal or liver dysfunction), and pre-existing conditions (e.g., infection) are risk factors for developing severe neutropenia (Lyman et al 2014) . Neutropenia is more common in females than males, the differences in total bone mass might explain the lower incidence of neutropenia seen in males. Greater marrow volume (as would be expected with men) might provide an individual with the ability to better tolerate chemotherapy and/or respond to an exogenous myeloid growth factor (Crawford et al 2005 , Lyman et al 2014 .
Severe neutropenia may be complicated by fever or febrile neutropenia. In this study about 58% patients had febrile neutropenia. Fever may be a common presentation with some malignancies, and their progression may parallel the occurrence of fever. Although the exact mechanism of tumor-associated fever is unclear, it is thought to be involved with inflammatory cytokines, such as TNF-, IL-1, and IL-6, which are produced either by host macrophages in response to the tumor or by the tumor itself. These pyrogenic cytokines cause elevations in temperature by acting on the hypothalamic temperature setpoint (Dalal & Zhukovsky 2006) . Filgrastim was used in this study to correct and reverse neutropenia. Filgrastim is a 175-amino acid recombinant protein expressed in Escherichia coli. The filgrastim peptide has the same amino acid sequence as endogenous human G-CSF with the exception that the backbone of the molecule is not glycosylated and the Nterminus is a methionine (Neumann & Foote 2012 , Holland & Gallin 2015 . Filgrastim is a late precursor in the cells maturation, in which it binds to GCSF receptor. The binding of filgrastim with GCSF's surface receptor on the haemopoietic cell is activated by phosphorylation of JAK2 and STAT molecules, a complex series of biochemical reactions by which the message is transmitted to the nucleus. The signal may activate pathways that cause the cell to enter cell cycle (replicate), differentiate, maintain viability (inhibition of apoptosis) or increase functional activity (e.g. enhancement of bacterial cell killing by neutrophils) , Mehta & Hoffbrand 2014 . Table 2 shows that the ANC level decreased almost 50% within 24 hours after the last dose of filgrastim. These observations are consistent with those of previous report. Upon discontinuation of G-CSF, ANC decreases by 50% within 1 to 2 days and returns to pretreatment levels within 1 week; WBC counts return to normal range in 4 to 7 days (UpToDate 2016).
Increases in ANC levels on days 1 to 5 has been hypothesized to be margination of the neutrophils to endothelial cells. The subsequent increase in circulating neutrophils may be caused by the release of mature neutrophils from the reserve pool of postmitotic mature myelocytes to complete the maturation cycle (Bekkering & Torensma 2013) . This cycle takes approximately 1 day, and the average time for a neutrophil to migrate from the reserve pool to the blood is about 10 days (Sieff 2016) . Therefore, the increasing trough 24-hour ANC level and the larger response on day 3 were probably caused by a combination of increased doserelated stimulation of myeloblast production in response to filgrastim; more rapid migration of mature neutrophils from the storage pool to the systemic circulation (since filgrastim is known to accelerate the release of peripheral blood progenitor cells into the circulation) (Molineux 2011 , Welte 2012 ).
Pharmacokinetics were linear at day 1 to 3, an increase dose of filgrastim resulted in a less functional proportional increase in ANC levels. However, the ANC levels were lower on day 4 to 5 compared with day 3. This may have been caused by a decrease in bioavailability, an increase in clearance, an increase in the volume of distribution or a combination of these factors. The changes in pharmacokinetic variables between day 3 and day 5 may be related to an increase in neutrophil mass by the fifth dosing day. One possibility is endocytosis by surface of G-CSF receptors. The decrease in plasma filgrastim concentration (and hence the increase in apparent clearance) may, therefore, result from the filgrastimdriven increase in the number of neutrophils and neutrophil precursors. Theoretically, at least, nonreceptor-dependent, neutrophil-mediated, accelerated filgrastim clearance may also contribute. These observations point to a negative feed-back mechanism inversely linking the numbers of neutrophils and serum G-CSF levels to limit the number of neutrophils in normal and disease states (Sieff 2016) .
The presence of endogenous growth factor of individual number, as well as response cells stem which also are individually, lead to different results and also are individually between patients who received filgrastim therapy, so that only 53% of patients achieved a therapeutic target for JNA = 1000 cells/mm 3 after administering filgrastim for 3-5 days. Nonetheless, these results need to be taken with caution in view of the limitations found: diverse populations and chemotherapy regimens. It is necessary to design further trials appropriately, well-powered for significant clinical outcomes and focused on high-risk patients. In addition, it is important to evaluate the cost-effectiveness of these agents in established febrile neutropenia.
CONCLUSION
Filgrastim therapy with dose of 10 µg/kgBW for 3 to 5 day has been able to reach the therapeutic target of 53% in acute leukemia children with neutropenia. The increased levels of ANC maximum was reached on the third day with increased levels of 9.5 fold.
